Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus
A newly engineered peptide called IBP-CP24 has the potential to be further developed as a long-acting anti-HIV drug that can be used alone or in combination with a broad neutralizing antibody for the treatment and prevention of HIV-1 infection, according to a study published Dec. 5 in the open-access journal PLOS Pathogens by Lu Lu and Shibo Jiang of Fudan University and Lishan Su of the University of North Carolina at Chapel Hill, and colleagues.
A new study published in The Journal of Infectious Diseases found that expansion of HIV treatment eligibility to include those under age 15 led to large and significant increases in initiation of antiretroviral therapy (ART) within 30 days of enrollment in care among 10- to 14-year-olds living with HIV.
New insight on how a type of cell facilitates the spread of HIV-1 has been published today in the open-access journal eLife.
An international team led by Professor Jerome Estaquier from Universite Laval's Faculty of Medicine may have discovered where in the body HIV takes refuge during antiretroviral treatment. Research conducted using an animal model indicates that the virus may hide in lymph nodes in the spleen and gut. The researchers believe those lymph nodes are the staging ground from which the virus prepares to relaunch the infection after treatment has stopped.
Many high-risk people eligible for medication to prevent HIV infection face barriers to obtaining a prescription, according to research by University of Massachusetts Amherst psychologist Avy Skolnik.
Many women in the WHO European Region, particularly those in their 40s, are diagnosed at a late stage of HIV infection when their immune system is already starting to fail. They are three to four times more likely to be diagnosed late than younger women. According to data for 2018 released today by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, women accounted for one-third of the 141,000 new HIV diagnoses in the Region.
Starting antiretroviral therapy within hours of birth drastically shrinks the reservoir of HIV virus -- an important step in efforts to cure infections -- and improves antiviral immune responses in newborns with HIV, shows a two-year study of a unique cohort of ten infants in Botswana.
As part of an international collaborative effort, investigators from Brigham and Women's Hospital conducted immunological and virological testing on newborns in Botswana, finding that initiating antiretroviral therapy immediately, rather than waiting a few weeks, provided measurable benefits for infants born with HIV.
Virologist Eric Cohen and his team have identified a way to thwart HIV infection at its very early stages.